Hear from our CEO, Adrian Treverton, about treating non-melanoma skin cancer patients safely during COVID. Patients most likely to develop basal or squamous cell carcinoma are those in the age range at greater risk of serious illness from COVID, so safe and short treatment options are important.
XBeam V2: FDA-Approved Treatment Planning Software
The Fastest, Safest Way to Plan Superficial & Orthovoltage Treatment XBeam V2 is the revolutionary, FDA 510(k)-cleared dose planning software designed to automate planning, eliminate risk, and seamlessly integrates with the Concerto system, Xstrahl’s clinical...
